ESSA Pharma Inc. (EPIX) News
Filter EPIX News Items
EPIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EPIX News Highlights
- For EPIX, its 30 day story count is now at 5.
- Over the past 10 days, the trend for EPIX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ESSA and AR are the most mentioned tickers in articles about EPIX.
Latest EPIX News From Around the Web
Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.
These Stocks under $10 Are Poised To ExplodeIn this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […] |
EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Masofaniten Clinical Programs ESSA Pharma Inc. (NASDAQ:EPIX) is developing masofaniten (EPI-7386), its next-generation antigen molecule that is designed to target the N-terminal domain (NTD) of the androgen receptor (AR) as a treatment for prostate cancer. Masofaniten is currently being evaluated in two |
EPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023EPIX stock results show that ESSA Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. |
ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...Corporate Update and Financial Highlights for the Year Ended September 30, 2023 |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023. |
Bullish ESSA Pharma Insiders Loaded Up On US$1.19m Of StockIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... |
Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 SharesRecent insider trading activity has caught the attention of market analysts and investors alike, as Director Franklin Berger executed a significant purchase of shares in ESSA Pharma Inc (NASDAQ:EPIX). |
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York. |
ESSA Pharma to Present at the Jefferies London Healthcare ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London. |
ESSA Pharma Enters into At-The-Market Equity Offering Sales AgreementESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$50.0 million in aggregate sales proceeds. No |